Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.
Clinical trials for at least seven Alzheimer's disease vaccines, aiming to leverage the immune system to eliminate disease-related proteins such as beta-amyloid or tau, are underway or completed.
This resurgence in vaccine development followed a setback over two decades ago when an initial vaccine attempt was abandoned due to 6% of volunteers developing life-threatening brain inflammation known as meningoencephalitis.
Researchers subsequently shifted focus towards a safer approach, utilizing precisely targeted ...